
NASDAQHealthcareMedical - Instruments & Supplies
أحدث البيانات المتاحة
35.12 US$
+0.05 US$ · +0.14%
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
جلسة التداول العادية
35.12 US$
+0.05 US$ · +0.14%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
نطاق اليوم
السعر الحالي 35.12 US$
نطاق 52 أسبوعًا
السعر الحالي 35.12 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
87
قيمة جذابة جدًا
المشاعر
66
صعودي
المخاطر
60
مخاطر أعلى من المعتاد
الزخم
57
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
نطاق اليوم
السعر الحالي 35.12 US$
نطاق 52 أسبوعًا
السعر الحالي 35.12 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 103.12 مليون USD | 86.67 مليون USD | 64.99 مليون USD | 45.84 مليون USD | 24.14 مليون USD |
| تكلفة البضاعة المباعة | 10.18 مليون USD | 8.14 مليون USD | 7.85 مليون USD | 6.36 مليون USD | 2.31 مليون USD |
| الربح الإجمالي | 92.94 مليون USD | 78.53 مليون USD | 57.14 مليون USD | 39.48 مليون USD | 21.83 مليون USD |
| البحث والتطوير | 5.07 مليون USD | 5.7 مليون USD | 4.13 مليون USD | 3.37 مليون USD | 558.7 ألف USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 78.72 مليون USD | 76.56 مليون USD | 56.99 مليون USD | 45.98 مليون USD | 28.05 مليون USD |
| نفقات التشغيل | 83.79 مليون USD | 85.25 مليون USD | 61.35 مليون USD | 52 مليون USD | 29.21 مليون USD |
| دخل الفوائد | 3.67 ألف USD | 21.98 ألف USD | — | 284.75 ألف USD | — |
| مصاريف الفوائد | 6.76 مليون USD | 3.13 مليون USD | 475.78 ألف USD | 284.75 ألف USD | 711 USD |
| الاستهلاك والإطفاء | 28.56 مليون USD | 4.92 مليون USD | 3.68 مليون USD | 2.37 مليون USD | 596.98 ألف USD |
| الدخل التشغيلي | 9.15 مليون USD | −6.72 مليون USD | −4.22 مليون USD | −12.52 مليون USD | −7.38 مليون USD |
| صافي الدخل | −37.56 مليون USD | −9.66 مليون USD | −4.3 مليون USD | −7.94 مليون USD | −7.92 مليون USD |
تم تحديث حقائق الشركة 12 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
35.00 US$
انخفاض محتمل بنسبة 0.34%عينة محدودة من 3 تقييمات
| الإجراء | تاريخ الاستحقاق | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
توزيعات الأرباحالقادمة | 29 يوليو 2027 | 33.00 US$Irregular | — | — |
استحقاق التوزيعات 29 يوليو 2027
33.00 US$
Irregular
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.